- Open Access
Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2
Molecular Cancer volume 13, Article number: 179 (2014)
A safe and effective adjuvant plays an important role in the development of a vaccine. However, adjuvants licensed for administration in humans remain limited. Here, for the first time, we developed a novel combination adjuvant alum-polysaccharide-HH2 (APH) with potent immunomodulating activities, consisting of alum, polysaccharide of Escherichia coli and the synthetic cationic innate defense regulator peptide HH2.
The adjuvant effects of APH were examined using NY-ESO-1 protein-based vaccines in prophylactic and therapeutic models. We further determined the immunogenicity and anti-tumor effect of NY-ESO-1-APH (NAPH) vaccine using adoptive cellular/serum therapy in C57/B6 and nude mice. Cell-mediated and antibody-mediated immune responses were evaluated.
The APH complex significantly promoted antigen uptake, maturation and cross-presentation of dendritic cells and enhanced the secretion of TNF-α, MCP-1 and IFN-γ by human peripheral blood mononuclear cells compared with individual components. Vaccination of NAPH resulted in significant tumor regression or delayed tumor progression in prophylactic and therapeutic models. In addition, passive serum/cellular therapy potently inhibited tumor growth of NY-ESO-1-B16. Mice treated with NAPH vaccine produced higher antibody titers and greater antibody-dependent/independent cellular cytotoxicity. Therefore, NAPH vaccination effectively stimulated innate immunity, and boosted both arms of the adaptive humoral and cellular immune responses to suppress tumorigenesis and growth of melanoma.
Our study revealed the potential application of APH complex as a novel immunomodulatory agent for vaccines against tumor refractory and growth.
NY-ESO-1 is a member of cancer/testis antigen expressed in multiple types of tumors, but not in normal adult tissues except for germ cells in testes and ovaries [1–3]. To date, a large number of major histocompatibility complex (MHC) class I- and class II-restricted NY-ESO-1 epitopes have been identified [4–7]. Studies have demonstrated that coordinated humoral and cellular immune responses against NY-ESO-1 occurred frequently in patients bearing NY-ESO-1-positive tumors [6, 8–10]. The relatively high immunogenicity and tissue distribution make NY-ESO-1 a promising candidate antigen for the development of tumor vaccines.
Vaccination with protein or peptide alone is insufficient to elicit an effective immune response. Adjuvant plays an important role in modifying the Th1/Th2 balance and increasing the magnitude and durability of adaptive immunity of subunit vaccines [11–13]. However, adjuvants licensed for human administration remain limited. Alum, the adjuvant for vaccine first approved by the United States Food and Drug Administration, is still the most commonly used adjuvant [14, 15]. Many studies have demonstrated its depot effect on antigens, resulting in its retention at the immunization site to prolonged antigen exposure [16, 17]. The administration of alum with protein or peptide elicits a stronger antibody-mediated immune response with a Th2 bias [18, 19]. Generation of a cellular immune response stimulated by vaccines with alum alone as an adjuvant is less well documented. As a poor CD8+ T cell adjuvant, alum alone is not suitable for therapeutic vaccines. Effective cytotoxic T-cell response may be stimulated in the presence of other additional adjuvants. Thus, the search for new, safe and potent complex adjuvant with the ability to enhance both the humoral and cellular immune responses remains a priority for the development of future vaccines.
Numerous polysaccharides (PSs) have been reported to act as potent immunomodulators with the function of stimulating innate and adoptive immune responses [20–22]. Many studies have demonstrated that polysaccharides in combination with antitumor monoclonal antibodies (mAbs) result in significant inhibition of tumor growth and enhancement of long-term survival [20–22]. β-glucans are polysaccharides extracted from yeast, barley, mushroom, seaweed, bacteria, and oat [20, 21, 23, 24]. Soluble β-glucans can prime neutrophils, macrophages, and NK cells for their cytotoxicity against iC3b-opsonized tumor cells resulting from the complement activation by antitumor mAbs [25, 26]. Dendritic cells (DCs) activated by bacterial β-glucan Curdlan can convert Treg cells into IL-17-producing T cells and simultaneously stimulate Th1, Th17 and cytotoxic T lymphocyte priming and differentiation . The immunomodulatory function of the bacterial polysaccharide was further illustrated by a study demonstrating that β-glucan enhances antitumor immune responses by regulating the differentiation and function of Treg cells and monocytic myeloid-derived suppressor cells . In particular, with a short production cycle, low production cost and no limitation of season and geographical restriction, bacterial extracellular polysaccharides may be a good source that can be exploited for immunotherapy. However, so far, little is known about bacterial polysaccharides as an adjuvant. Recently, for the first time, we have studied the immunomodulatory effect of alum-PS complex (AP). The AP complex can stimulate effective antigen-specific humoral immune response, but has limited protective cellular immune responses. Thus, improvements are required before the antitumor vaccine becomes more effective against cancer.
HH2 (VQLRIRVAVIRA-NH2) is a short synthetic innate defense-regulator peptide (IDRs). The immunomodulatory functions of IDRs include indirect or direct recruitment of DC, neutrophils and macrophages, modulation of DC and macrophage differentiation, stimulation of production of chemokines (monocyte chemoattractant protein-1, MCP-1) and cytokines (IL-8, IFN-γ), limitation of potentially harmful inflammation mediated by bacterial products, and adjuvant activity stimulating innate immune response and promoting a vigorous adaptive response [29–31]. The development of natural host defense peptides has been problematic due to their hemolytic activity, cytotoxicity toward mammalian cells and stimulation of degranulation of mast cells [32, 33]. With the advantage of more optimized immunomodulatory activities and low cytotoxicity over natural IDRs, the synthetic mimics (e.g. HH2) of innate defense regulators may be attractive candidates for immunotherapy.
In the present study, we developed an alum-polysaccharide-HH2 (APH) complex as a novel adjuvant, and examined the antitumor effect of the NY-ESO-1 protein vaccine with the APH adjuvant in a melanoma model. The APH complex adjuvant dramatically enhanced the quantitative strength of both NY-ESO-1 specific humoral and cellular immune responses against melanoma formation and progression. Therefore, our findings indicate that APH is a new promising immunomodulatory agent for vaccines against tumor refractory and growth.
The PS-HH2 complexes induce chemokines in peripheral blood mononuclear cells
Preliminary studies demonstrated that HH2 and the TLR ligands are potent inducers of MCP-1, a chemokine that is chemotactic for monocytes/macrophages, NK cells, and neutrophils . Some cytokines are important in innate immunity, such as TNF-α and IFN-γ. Thus, MCP-1, TNF-α, and IFN-γ were selected to screen for the development of immunostimulatory agents. This synergistic effect was calculated as the total release of chemokines induced by a PS-HH2 complex divided by the additive release of chemokines induced by the individual complex components. A cut-off level of ≥2 was selected to indicate synergy. As shown in Additional file 1: Figure S1A, the 1:2 ratio of PS: HH2 resulted in a maximal IFN-γ induction (1352 ± 95 pg/ml) among these groups. The potent induction of TNF-α expression in vivo showed an increasing trend with an increasing concentration of HH2. Among the PS-HH2 complexes, 1:4 and 1:2 (wt/wt) ratios of PS: HH2 resulted in a most potent induction of TNF-α expression (699 ± 48 pg/ml and 651 ± 104pg/ml, respectively) in vitro and independently showed a synergistic effect of 2.1 ± 0.1 and 2 ± 0.2, respectively (Additional file 1: Figure S1B). Similarly, 1:4 and 1:2 (wt/wt) ratios of PS: HH2 resulted in a most potent induction of MCP-1 expression (16064 ± 2051 pg/ml and 13725 ± 1480 pg/ml, respectively). There was no significant difference between the two groups (Additional file 1: Figure S1C). Since safety is as important as potency for an adjuvant, we further investigated the potential cytotoxic effect of the PS-HH2 complexes by monitoring the release of hemoglobin from red blood cells and lactate dehydrogenase (LDH) from peripheral blood mononuclear cells (PBMCs). Our data showed that the tested PS-HH2 complexes resulted in minimal or no release of hemoglobin or LDH from red blood cells (RBCs) (Additional file 1: Figure S1D) and PBMCs (Additional file 1: Figure S1E), respectively. Thus, 1:2 (wt/wt) PS: HH2 formulation was chosen to further examine its adjuvant effect for NY-ESO-1 below.
NAPH vaccine inhibits tumor growth in a melanoma model
In the prophylactic model (Figure 1A and Additional file 2: Tables S1 and S2), the NY-ESO-1-B16 melanoma grew rapidly in control mice, with mean tumor volume of approximately 1675 mm3 by Day 22. In contrast, the tumor growth was significantly inhibited in the NY-ESO-1-alum-PS (NAP) group (P < 0.05 versus control). Of more interest, the tumor growth was significantly delayed in the NAPH group, in which nearly half of these mice were still tumor-free by Day 22 (P < 0.005 versus control). These results indicated that vaccination of mice with the NAPH vaccine induced an effective NY-ESO-1-specific antitumor immune response, which was sufficient to suppress the tumorigenesis and growth of NY-ESO-1-B16 melanoma.
In the therapeutic model (Figure 1B and Additional file 2: Tables S1 and S2), mice in the control group developed large tumors (mean volume, 2431 mm3) by Day 23 after NY-ESO-1-B16 melanoma cells were inoculated into mice. The mean volumes of melanoma in the NY-ESO-1-alum (NA), NY-ESO-1-alum-HH2 (NAH), NAP, and NAPH group were 2079, 1434, 1155, and 773 mm3, respectively. The tumor growth in the NS or NA-immunized groups was progressive, but in NAPH-treated group was significantly retarded (P < 0.05 versus control).
The anti-tumor effect of the NAPH vaccine was further studied in an adoptive cellular/serum therapy model. As shown in Figure 1C and Additional file 2: Tables S1 and S2, the mean volumes of melanoma in mice transferred with splenocytes from NS, NA, NAH, NAP and NAPH groups were 2699, 2052, 1879, 1858, and 1282 mm3, respectively. Tumor growth of NAPH-treated mice was significantly inhibited after passive cellular therapy (P < 0.05 versus control).
To determine whether the serum was sufficient to mediate the antitumor response, serum from the vaccinated mice was passively transferred to recipient C57/B6 mice for 10 consecutive days one day after the tumor challenge (Figure 1D). C57/B6 mice receiving serum from naïve mice all succumbed to tumors. In contrast, serial passive transfer of serum from the NAPH group significantly inhibited NY-ESO-1-B16 tumor growth (P < 0.05 versus control).
To further study the effect of passive serum therapy on A375 human melanoma model, A375-bearing mice were subjected to passive serum therapy, as described above, with serum from treated or naïve Balb/c mice (Figure 1E). Immune serum from the NAPH group caused retardation or regression of A375 tumor xenografts. Upon sacrifice, the mean tumor volumes from mice treated with NAPH or non-immune sera were 328 mm3 and 1521 mm3, respectively, with a significant difference (P < 0.005) (Additional file 2: Tables S1 and S2).
No marked toxicity, including weight loss, ruffed fur, diarrhea, and anorexia, was observed during the entire vaccination in the preventive model. To evaluate the potential toxic effects on vital organs in treated mice, hematoxylin-eosin staining (HE staining) was performed. There were no obvious pathological changes in the heart, liver, spleen, lung and kidney of the treated mice (Additional file 3: Figure S2).
NAPH vaccine effectively stimulates an innate immune response
The immunostimulatory effect of the NAPH vaccine on innate immunity was examined by measuring the NK-cell activity assay 48 h after the first immunization. As shown in Figure 2, NK-cells from control mice were unable to lyse YAC-1 cells when total splenocytes were used as effectors; there was no significant difference between the NS group and NA or NAP group in NK-cell-mediated cytolysis of YAC-1 cells, while the cytotoxicity in the NAH group was higher than that in the above-mentioned groups (P < 0.005). Splenocytes isolated from NAPH-treated mice had a greater cytotoxic activity against YAC-1 cells than that from the NAP group (P < 0.001). Therefore, the NAPH vaccine was able to effectively stimulate innate immunity to eradicate MHC-I-deficient tumors in vivo.
NAPH vaccine enhances antigen-specific antibody immune response
Sera from naïve or treated mice were analyzed using ELISA for the presence of total NY-ESO-1-specific IgG and different IgG subtypes one week after the third immunization. NAPH-immunized mice developed significantly higher titers of NY-ESO-1-specific IgG than other groups (P < 0.05) (Figure 3A). Although there was an increasing trend for IgG2a titer in NAPH group compared with other groups, these differences did not achieve statistical significance (P > 0.05) (Figure 3B). Sera obtained from the NAPH group showed substantial higher titer of IgG1 than that from other groups (P < 0.005) (Figure 3C). Antibody binding to natural NY-ESO-1 expressed by NY-ESO-1-B16 melanoma cells in the NAPH group was the highest among the groups (P < 0.05). The serum binding positive index of NY-ESO-1-B16 increased with a decreased serum dilution ratio (Figure 3D).
To investigate whether the elicited antibody mediates antibody-dependent cell-mediated cytotoxicity (ADCC) activity (Figure 3E), NY-ESO-1-B16 melanoma cells were utilized as target cells after coating with sera from different groups. Sera from control showed no lysis of NY-ESO-1-B16 melanoma cells. Sera from NAPH-treated mice induced a significant ADCC particularly when the effectors were derived from the NAPH group (P < 0.05).
Induction of potent cytotoxic T lymphocytes (CTL) responses plays a critical role in anticancer activity of NAPH vaccine
To assess the cell-mediated immune response stimulated by the NAPH vaccine, CTL activity was performed using the 51Cr release assay. Splenocytes were separated and stimulated with 10 μg/ml NY-ESO-1 for 16 h and used as effectors. CTL assays (Figure 4A) were validated by the ratio of spontaneous release to maximum release. These effectors in NAPH showed 2.2-fold more tumor-killing activity than that in the NA group, and 1.2-fold more than that in the NAP or NAH groups (P < 0.05 versus control). In the ELISPOT assay, the number of spot-forming cells (SFCs) after in vitro stimulation with NY-ESO-1 is shown in Figure 4B. There was a more pronounced increase in SFCs secreting IFN-γ/IL-4 in the NAP-immunized group than the NA or NAH group (P < 0.05). The number of SFCs secreting IFN-γ instead of IL-4 in the NAPH group was 3.1-fold greater than that of the NAP group (P < 0.05). To further confirm this observation, splenocytes obtained from naïve or treated mice were stimulated with NY-ESO-1 protein, and the frequency of IFN-γ-secreting CD4+/CD8+ T cells was measured via flow cytometry (Figure 4C). The mean fluorescence intensity of IFN-γ expression by CD4+ and CD8+ T cells was the highest in the NAPH group (P < 0.05 versus NS and NA groups).
The NAPH vaccine increases infiltrating lymphocytes in tumors
Tumor infiltrating lymphocytes (TILs), a primary immune component infiltrating solid tumors, are considered to be the manifestation of the host antitumor reaction. Immunohistochemistry analyses were performed to study TILs in tumors. The intensity of infiltration by CD4, CD8 and CD57 lymphocytes was studied (Figure 5A). There was a significant increase in the intensity of infiltration of CD4+ and CD8+ T cells in tumors from the NAH and NAP groups compared with the NS and NA groups (P < 0.005). NK cell infiltration in tumors from the NAP group was higher than that from the NS and NA groups (P < 0.005). Importantly, a large number of CD4+, CD8+ T cells and NK cells infiltrated were observed in the tumors from the NAPH group, compared with the NS group (P < 0.001) (Figure 5B).
The PS-HH2 complex promotes antigen uptake and cross-presentation of dendritic cells
To investigate the effect of complex adjuvant on antigen uptake of DCs, we directly visualized the uptake capacity of NY-ESO-1. As shown in Figure 6A, the mean fluorescence intensity values of NY-ESO-1 alone, NH, NP and NAPH stimulated DCs were 9.5, 18.9, 64.0 and 118.0, respectively. There was a significantly enhanced uptake of fluorescent intensity of controls in DCs after stimulation with NP complex for 3 h. In contrast, PS and HH2 synergistically enhanced approximately 12.5 times higher mean fluorescence intensity than NY-ESO-1 alone. Efficient cross-priming has physiological importance for the initiation of cellular immune responses against tumors in the absence of the classical MHC-I presentation pathway . Thus, co-localization of NY-ESO-1 and intracellular organelles in DCs was analyzed using confocal microscopy. As shown in Figure 6B, there was significantly more NY-ESO-1 adjuvant with PS or HH2 processed in compartments expressing LMP-2 compared with the control group. Co-localization experiment demonstrated that NY-ESO-1 localized to LMP-2/ LAMP-1-expressing compartments was predominantly in the NPH group versus other groups. PS-HH2 complex adjuvant could significantly enhance the NY-ESO-1 uptake and cross-presentation of DCs. Furthermore, we investigated the effect of PS-HH2 complex adjuvant on the maturation of DCs. Treatment of DCs with PS-HH2 for 24h resulted in an up-regulation of surface maturation markers, including CD80, CD86, and MHC- II (Figure 6C).
Alum and PS-HH2 synergistically activate the Syk-PI3K-NF-κB signaling pathway for DC activation
To further understand the molecular mechanisms involved in adjuvant complex-induced DCs, we examined the activation of Syk-PI3K/Akt signaling pathway by adjuvant complex stimulation. As shown in Figure 7, the phosphorylation of Syk and Akt was increased markedly in DCs after 15-min stimulation with APH complex, compared with alum or PS-HH2. Alum and PS-HH2 stimulation for 30 min synergistically triggered the activation of NF-κB, as assessed by the phosphorylation level using the phosphor-specific antibodies to IkBα and NF-κB. Both Syk and PI3K/Akt act as upstream regulators on NF-κB activation. Therefore, alum and PS-HH2 synergistically activates the Syk-PI3K-NF-κB signaling pathway.
Anticancer vaccines have been studied for decades, however, to date, the clinical effects of these vaccines remain limited. The development of vaccines has been hampered by the paucity of vaccines that are able to elicit an antitumor immune response to eliminate human tumors safely and effectively. Furthermore, the ability to sustain an effective antitumor immune response through repeated immunizations may be an important feature of therapeutic anticancer vaccines [34, 35]. Recombinant adenoviral vector encoding the full sequence of NY-ESO-1 cDNA has been developed with some success [36, 37]. However, the NY-ESO-1 DNA vaccine could not be used repeatedly due to the induction of anti-vector neutralizing antibodies. Thus, improvements are required. Adjuvant systems capable of enhancing the antigen specific immune response provide an attractive alternative strategy.
Here, for the first time, we present evidence that the APH complex adjuvant significantly enhanced the immunogenicity of NY-ESO-1 protein. The APH complex adjuvant could promote NY-ESO-1 uptake and maturation of DCs. Subsequent maturation of NAPH vaccine-pulsed DCs resulted in efficient targeting of full-length NY-ESO-1 proteins in the MHC-I pathway for cross-presentation to antigen-specific CD8+ T cells.
The synergetic effect on the enhancement of anti-tumor immune response among alum, PS and HH2 might be attributed to the following aspects: alum vaccination resulted in an increase in IL-4-producing cells to promote Th2-type immune responses . Several studies have demonstrated that alum triggers lysosomal membrane damage with subsequent activation of the Nlrp3 inflammasome for its adjuvanticity [39, 40]. Simultaneously, alum engages lipid rearrangements of DCs, resulting in an aggregating response of ITAM-Syk-PI3K-mediated phagocytes . Alum can also accelerate the transmission of admixed antigen through the plasma membrane of DCs . PS isolated from E. coli, a member of β-glycan, has a potent adjuvanticity to stimulate innate immunity and modulate the adoptive immune response. β-glycans are capable of priming/activating the iC3b receptor of neutrophils, macrophages, and NK cells for cytotoxicity against iC3b-opsonized tumor cells dependent on the CR3-Syk-PI3K pathway . Our study demonstrated that alum and PS synergistically could activate the Syk-PI3K signaling pathway. HH2, a short synthetic innate defense-regulator peptide based on bovine bactenecin, is chemotactic for immature DCs, monocytes, neutrophils, and macrophages, and subsequently activates the MAPK-NF-κB pathway to up-regulate genes involved in innate immunity, such as IL-8 and MCP-1 . The upstream tyrosine kinase Syk has an important role in NF-κB-mediated inflammatory responses. Therefore, alum, PS and HH2 might synergistically activate the NF-κB signaling pathway to enhance the antitumor immune response. Furthermore, due to its cationic property, HH2 facilitates antigen transport, uptake and presentation by antigen-presenting cells (APCs) . Importantly, HH2 can enhance and modulate the adoptive immune response. However, the synergetic mechanism of the adjuvants remains to be further studied.
The generation of tumor-specific CTLs is well correlated with the prevention and eradication of malignant cells in tumor models. Vaccine-induced antibodies promote CD8+ T cell cross-priming via antibody-aided cross-presentation. Antibody-aided cross-priming of tumor specific CTLs could also contribute to the antitumor effect. Thus, an integrative weapon to recruit all available components of the immune system should be explored . Our data has demonstrated that the NAPH vaccine could effectively stimulate NK-cell activity against MHC-I-deficient tumor. The NY-ESO-1-specific antibody titers and antibody-dependent cytotoxicity were evidently induced after NAPH vaccinations. In particular, the anti-serum obtained from the NAPH group could mediate tumor regression in a nude mouse model of human melanoma via adaptive transfer therapy. Furthermore, antitumor CD8+ CTLs were efficiently reactivated with the help of CD4+ T cells after NAPH immunization. The antitumor activity could be contributed to integrative immunoregulation, such as activation of NK cells, increase in adaptive T-cell responses, elevation in neutralizing antibody specific for NY-ESO-1, induction of ADCC activity against antibody-coated tumor cells, enhancement of Th1-type cytokine secretion (IFN-γ), and accentuation of CTL activity. Thus, NAPH may be exploited into a potent anticancer vaccine that could stimulate innate immune response and trigger the arms of the adaptive immune response, thus significantly inhibiting the tumorigenesis and growth of melanoma.
NY-ESO-1 is a promising tumor-associated target for vaccine-based immunotherapy of cancers. It is a non-mutated self-antigen that if frequently expressed in various types of human tumors, including melanoma, prostate, breast, lung, and transitional cell bladder carcinoma . Furthermore, NY-ESO-1 has been found to share 94% identity with another cancer-testis antigen LAGE-1, at the nucleotide level. Although they are frequently co-expressed, 45% of melanoma patients have tumors expressing either one or the other antigen . It has been reported that the NY-ESO-1 vaccine could also induce CD8+ T cells to kill tumor cells expressing LAGE-1 . Thus, the NY-ESO-1 vaccine may serve as a common vaccine targeting many types of tumors.
In conclusion, here we show a new safe anti-tumor vaccine that could effectively induce innate immunity and NY-ESO-1-specific adoptive immune responses to inhibit the tumorigenesis and growth of melanoma. The APH complex adjuvant is promising as a novel immunomodulatory agent to mediate and enhance antigen-specific immune responses to prevent tumor refractory and treat cancer.
Materials and methods
Female C57/B6 mice (4-6 weeks old) were purchased from HuaFukang Biological Technology Company (Beijing, China) and maintained at the Animal Center of State Key Laboratory of Biotherapy of Sichuan University for 2 weeks of adaptive feeding prior to the start of experiment. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Sichuan University.
B16-F10 melanoma cells (ATCC, Rockville, USA) were transfected with the constructed plasmid pcDNA3.1 /NY-ESO-1 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Next, the cells were grown with DMEM supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, USA) containing 800 μg/ml of G418 (Sigma, St. Louis, MO). B16 clones stably expressing NY-ESO-1 (NY-ESO-1-B16) were generated by limit-dilution cloning, which were confirmed by RT-PCR and Western blotting. Tumor cells were cultured and inoculated into mice if the viability was greater than 96%. All cell lines were free of mycoplasma infection. The ability of NAPH-immunized mice to reject NY-ESO-1-B16 melanoma in vivo was independently assessed in the protective and therapeutic models.
In vitro cytokine secretion
To examine the effect of PS-HH2 combination on cytokine secretion, a constant amount of PS (10 μg) was combined with increasing concentrations of HH2, and used to treat PBMCs, followed by the chemokine/cytokine induction assay. Briefly, PS and HH2 were mixed with five ratios of PS: HH2 ranging from 4:1 (wt/wt) PS: HH2 to 1:4 (wt/wt) PS: HH2. Venous blood samples from healthy volunteers were collected and separated by centrifugation over a Ficoll Paque Plus (GE Healthcare Bio-sciences Corp., Piscataway, NJ, USA). PBMCs (5 × 105) were seeded into a 24-well plate at 1 × 106 cells/ml and stimulated with various PS-HH2 complexes, or the components alone. Following the stimulation for 24 h, the supernatants were collected and monitored for IFN-γ, TNF-α and MCP-1 levels using ELISA. In addition, the cytotoxicities of the PS-HH2 formulations were examined by monitoring the release of hemoglobin from red blood cells and LDH from human PBMCs as previously described by Kindrachuk et al. .
Vaccines and immunization protocols
The expression and purification of NY-ESO-1 were prepared by the following steps. Briefly, hNY-ESO-1 (Invitrogen, Carlsbad, CA) was engineered into a bacterial expression plasmid PET32a (Invitrogen, Carlsbad, CA). The E.coli strain BL21 (DE3)-bearing recombinant PET32a-NY-ESO-1 was induced with IPTG for protein production. The crude NY-ESO-1 protein was expressed as soluble fusion constructed with N-terminal thioredoxin-His6-EK protease site tag (Trx-NY-ESO-1). The bacteria were lysed using a high-pressure homogenizer (APV 2000, Lubeck, Germany). NY-ESO-1 was purified via four process steps, which included Ni-chelating Sepharose affinity chromatography (GE Healthcare, Piscataway, NJ), excision of the Trx-His6-tag, removal of the Trx-His6-tag with second Ni-chelating Sepharose affinity chromatography, and Q-ion-exchange chromatography (GE Healthcare, Piscataway, NJ). The endotoxin level of the final purified NY-ESO-1 protein was measured using the QCL-1000 Endpoint Chromogenic Limulus Amebocyte Lysate (LAL) Assay kit (Lonza, Basel, Switzerland).
To prepare vaccines, PS (20 Sigma, St. Louis, MO) was first formulated with HH2 (Ketai Biotechnology Company, Shanghai, China) and alum (Brenntag Biosector, Frederikssund, Denmark) at 37°C for 10min, followed by the addition of NY-ESO-1, in which the endotoxin levels were approximately 0.02EU/μg. Briefly, 20 μg PS was mixed with 40 μg HH2, and then combined with 125 μg alum, followed by mixing with 5 μg recombinant NY-ESO-1 protein in PBS with a total volume of 100 μl. Components were omitted at the appropriate steps for the single- and two-component formulations.
In the preventive model, C57/B6 mice (n = 12) were vaccinated subcutaneously (s.c.) 3 times (on Days 0, 14, and 28) with NA, NAP, NAH, or NAPH. The mice treated with PBS were used as controls. Two weeks after the third immunization, the mice were challenged with NY-ESO-1-B16 cells. Briefly, the tumor cells (2 × 105) were injected s.c. on the back and tumor volume was measured every 3 days when mice showed mammary neoplasia. Tumor volume was calculated by the following formula: tumor volume = 0.5 × length (mm) × [width (mm)]2.
In the therapeutic model, mice were inoculated s.c. with 2 × 105 NY-ESO-1-B16 cells in 0.1 ml serum-free medium on Day 0. Once the tumor became palpable (>50 mm3), the mice were randomly divided into groups (12 mice/group) and immunized 3 times (on Days 5, 12 and 19) using the above-mentioned vaccines. The tumor size and body weight were measured as described above.
Detection of antibody titer and antibody-dependent cellular cytotoxicity
Seven days after the third immunization, serum was collected and NY-ESO-1 specific antibody was determined using ELISA as previously described . Briefly, plates (Nunclon, Roskilde, Denmark) were coated with NY-ESO-1 protein (0.1 μg/well) overnight at 4°C followed by blocking with 5% non-fat dry milk and 0.05% Tween-20 in PBS. Next, sera were incubated at different dilutions and goat anti-mouse IgG (1:3000 dilution; Zhongshan, Beijing, China), anti-mouse IgG2a, or anti-mouse IgG1 conjugated with horseradish peroxidase (1:400 dilution; Southern Biotech, Birmingham, AL). After the peroxidase color reaction was developed with TMB, the plates were read on an ELISA reader at A450.
Antibody binding to natural NY-ESO-1 expressed by NY-ESO-1-B16 melanoma cells was further assessed using a flow cytometry-adapted methodology previously reported by Piechocki et al. . Briefly, 3 × 105 NY-ESO-1-B16 cells were fixed and permeabilized with ice-cold 100% methanol for 10min. After incubation with diluted (1:400, 1:800, 1:1600, and 1:3200) mouse serum for 1 h at 4°C, the samples were washed with phosphate buffered saline (PBS), stained with FITC-conjugated anti-mouse IgG (BD Pharmingen, San Jose, CA) for 30min at 4°C, washed, and analyzed using BD FACS calibur flow cytometry (BD Biosciences).
To determine antibody-dependent cellular cytotoxicity, 1 × 106 NY-ESO-1-B16 cells were incubated with pooled sera at 1:20 dilution, and labeled with Na51CrO4 for 1 h at 37°C. After the unbound antibodies and excess chromium were removed, the cells (1 × 104) were incubated with mouse splenocytes obtained from naïve or treated mice for 4 h at 37°C. Finally, cell-free supernatant was collected and the release of chromium was measured using a gamma counter (LKB Wallac, Turku, Finland). The percent lysis was determined according to the formula: (experimental lysis-spontaneous lysis)/(maximum lysis – spontaneous release) × 100.
NK assay and CTL
The activity of NK cells was determined using a classic NK assay against YAC-1 cells as previously described . Briefly, YAC-1 cells were labeled with Na51CrO4, washed, and incubated with splenocytes obtained from naïve or treated mice 48 h after the first immunization for 4 h at 37°C.
One week after the third immunization, splenocytes were isolated, sensitized with NY-ESO-1 protein (10 μg/ml for 16 h at 37°C), and incubated with Na51CrO4 labeled NY-ESO-1-B16 cells at serial Target: Effector ratios (1:10, 1:20, and 1:40). The supernatants were harvested, and the released radioactivity was measured using a gamma counter (LKB Wallac, Turku, Finland).
IFN-γ intracellular staining and ELISPOT assays
For intracellular staining of IFN-γ in CD4+ and CD8+ T cells, splenocytes were isolated one week after the last immunization, re-stimulated with NY-ESO-1 (10 μg/ml) for 1 h at 37°C, incubated for an additional 6 h in Golgi Plug and harvested, followed by staining with PerCP-anti-mouse CD4 and PE-anti-mouse CD8α. After fixation and permeabilization using a Cytofix/Cytoperm Kit, intracellular staining was achieved with FITC-anti–mouse IFN-γ (all from BD Bioscience/Pharmingen) according to the manufacturer’s instructions. After several washes, the cells were analyzed using BD FACS Calibur flow cytometer.
Splenocytes were harvested from naïve or immunized mice one week after the final immunization, and ELISPOT assays were performed using the mouse IFN-γ/IL-4 Dual-Color ELISpot kit (R & D systems, Minneapolis, USA) according to the manufacturer’s instructions. Briefly, 5 × 105 splenocytes were stimulated with 10 μg/ml NY-ESO-1 in 100 μl/well RPMI 1640 supplemented with 10% FBS at 37°C for 48 h. Next, the plates were developed using an enzyme-linked colorimetric assay. The spots were quantified using an ELISPOT plate reader and software (Beijing Dakewe Biotech Company, Beijing, China).
Adoptive transfer studies
One week after the third immunization, splenocytes and serum were isolated aseptically from naïve or treated C57/B6 mice for passive serum/cellular therapy. Next, 2 × 107 donor splenocytes were injected i.v. into recipient mice for 2 consecutive days from the first day after tumor inoculation, as described . For serum adoptive therapy, tumor-bearing mice were injected i.v. with 0.1 ml of the serum from Days 1 to 10 after the NY-ESO-1-B16 implantation.
To study of the passive serum therapeutic effect on human melanoma, female nude mice (5-7 weeks old) received s.c. inoculations of 5 × 106 A375 cells on Day 0. Tumor-bearing mice were subjected to passive serum therapy, as described above.
HE staining and immunohistochemistry
Tumor specimens, as well as heart, liver, spleen lung and kidney samples were fixed in 4% paraformaldehyde, and dehydrated by a series of graded alcohol solutions. Paraffin sections (5 μm) were prepared, and stained with H & E. For immunohistochemistry of tumor samples, slides were deparaffinized with xylene and rehydrated through graded alcohol solutions. Antigen retrieval was performed using steamed heat and endogenous peroxidase was quenched by 30 min incubation in 3% H2O2. Sections were separately incubated with anti-CD4, anti-CD8 and anti-CD57 mAbs (1:100 dilution; Abcam, Cambridge, MA) overnight at 4°C. Sections were then incubated with biotinylated anti-mouse antibody and streptavidin-biotinylated peroxidase complex. The peroxidase color reaction was developed with DAB chromogen. Finally, all sections were counterstained with Meyer’s hematoxylin. Infiltrated lymphocytes were observed and quantified under a microscope at 400× magnification. Intensity of lympocyte infiltration in the tumors was determined by the mean positive cell counts in the dermis around the NY-ESO-1-B16 tumor per field (10 randomly selected high power fields/slide). For each site, 3 pathologists performed a blind read of the glass slides.
Antigen uptake and cross-presentation of DCs stimulated by the PH complex
Immature DCs derived from bone marrow were isolated from mice as previously described . The phenotype of DCs was analyzed using a BD FACS Calibur flow cytometer. Briefly, C57BL/6 bone marrow cells were isolated and cultured in the presence of murine rIL-4 (10 ng/ml) and rGM-CSF (10 ng/ml) (both from Sigma). Non-adherent and loosely adherent immature DCs were harvested on Day 5 for experiments.
NY-ESO-1 protein was labeled with green fluorescence using a Pierce NHS-Fluorescein Antibody Labeling Kit (Invitrogen) according to the manufacturer’s instructions. NHS-labeled NY-ESO-1 (10 μg/ml) was combined with PS (20 μg/ml), HH2 (40 μg/ml), or PH complex at 37°C for 15 min. DCs were plated at 2 × 105 cells/well in a 24-well plate and stimulated with protein or protein adjuvant complex. After incubation at 37°C for 3 h, the cells were fixed with 4% paraformaldehyde and stained for DNA with DAPI. The NY-ESO-1 uptake by DCs was observed under a confocal microscope.
For the NY-ESO-1 internalization studies of DCs, NY-ESO-1 protein was labeled with red fluorescence using the Alexa Fluor 594 protein labeling kit (Invitrogen) according to the manufacturer’s instructions. DCs were incubated with Alexa Fluor-labeled NY-ESO-1 or NY-ESO-1/complex adjuvant for 3 h at 37°C. After incubation, the cells were fixed in 4% paraformaldehyde and permeabilized in 0.1% Triton X-100/PBS. After Fc blocking with anti-mouse CD16/CD32 (BD Bioscience), the cells were separately stained with mouse FITC-anti-LAMP1 for late endosomes/lysosomes or FITC-anti-LMP2 antibody (both from BD) for proteasomes. Finally, DNA was stained with DAPI. The fluorescence intensity was calculated using the Image Pro Plus 6.0 software (Media Cybernetic, Inc. Silver Spring, USA). The background levels were determined by averaging the fluorescence intensity of controls. The mean fluorescence intensity was calculated for each photo and normalized by dividing the intensity by the number of cells. Significance was considered if the fluorescence intensity was 3 times higher than the other group.
After 24 h incubation with NY-ESO-1 or NY-ESO-1/adjuvant formulation, the phenotype of DC was analyzed using triple-color staining. The PERCP-anti-CD80, FITC-anti-CD86, PE-anti-MHCII were obtained from BD Biosciences PharMingen (San Diego, CA). Briefly, after antigen or antigen/adjuvant stimulation, the cells were first incubated with anti-mouse CD16/CD32 (BD Bioscience) to prevent nonspecific binding of mAbs to Fcγ receptors. Next, the DCs were stained with fluorochrome-conjugated antibodies. After washing, cells were analyzed using a BD FACS Calibur flow cytometer.
Immature DCs derived from bone marrow were incubated and harvested on Day 5 for Western blot analysis. After treatment with alum (125 μg/ml), PS-HH2 (PS: 20 μg/ml, HH2: 40 μg/ml), or alum-PS-HH2 complex for 0, 5, 10, and 30 min, respectively, DCs were washed twice with Tris buffered saline (TBS) and lysed with RIPA buffer. The protein concentration was determined using the BCA assay. Equal amount of protein were separated by SDS-PAGE and transferred on polyvinylidene fluoride membranes (Millipore, Billerica, MA). After blocking with 5% non-fat milk /TBS-T (TBS containing 0.1% Tween 20), the blots were probed overnight at 4°C with antibodies to phospho-Syk, phospho-Akt, phospho-IkBα and phospho-NF-κB antibodies (all from Cell Signaling Technology, Beverly, MA), respectively. Blots were developed using a Supersignal West Pico chemiluminescent substrate kit (Pierce, Rockford, IL), following incubation with appropriate horseradish peroxidase-conjugated secondary antibody. GAPDH was detected on the same membrane and used as the loading control.
Data were analyzed using the SPSS statistical software (IBM, Chicago, USA). Multiple group comparisons were performed using one-way analysis of variance followed by Tukey’s multiple-range testing. All values are depicted as the means ± SD. P < 0.05 was considered statistically significant.
- E.coli :
Tumor necrosis factor α
Monocyte chemotactic protein-1
Innate defense regulators
Peripheral blood mononuclear cells
Antibody-dependent cell-mediated cytotoxicity
Cytotoxic T lymphocytes
Tumor infiltrating lymphocytes
Major histocompatibility complex
Reverse transcription polymerase chain reaction
Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O’Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M: Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A. 2007, 104: 8947-8952. 10.1073/pnas.0703395104
Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, Miyoshi Y, Tamaki Y, Matsuura N, Noguchi S, Old LJ, Nakayama E, Monden M: NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 2004, 64: 2199-2204. 10.1158/0008-5472.CAN-03-3070
Caballero OL, Chen YT: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009, 100: 2014-2021. 10.1111/j.1349-7006.2009.01303.x
Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A: Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4 (+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000, 191: 625-630. 10.1084/jem.191.4.625
Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, Karbach J, Jager E, Cameron BJ, Lissin N, Vyas P, Chen JL, Cerundolo V, Jakobsen BK: Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol. 2006, 176: 7308-7316. 10.4049/jimmunol.176.12.7308
Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF: CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A. 2001, 98: 3964-3969. 10.1073/pnas.061507398
Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF: Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol. 2000, 165: 1153-1159. 10.4049/jimmunol.165.2.1153
Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998, 187: 265-270. 10.1084/jem.187.2.265
Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P: Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000, 60: 4499-4506.
van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G: NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005, 105: 3939-3944. 10.1182/blood-2004-09-3707
Garlapati S, Facci M, Polewicz M, Strom S, Babiuk LA, Mutwiri G, Hancock RE, Elliott MR, Gerdts V: Strategies to link innate and adaptive immunity when designing vaccine adjuvants. Vet Immunol Immunopathol. 2009, 128: 184-191. 10.1016/j.vetimm.2008.10.298
Tofukuji S, Kuwahara M, Suzuki J, Ohara O, Nakayama T, Yamashita M: Identification of a new pathway for Th1 cell development induced by cooperative stimulation with IL-4 and TGF-beta. J Immunol. 2012, 188: 4846-4857. 10.4049/jimmunol.1103799
Ellebedy AH, Lupfer C, Ghoneim HE, DeBeauchamp J, Kanneganti TD, Webby RJ: Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc Natl Acad Sci U S A. 2011, 108: 2927-2932. 10.1073/pnas.1012455108
McKee AS, Michael MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW, Marrack P: Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol. 2009, 183: 4403-4414. 10.4049/jimmunol.0900164
HogenEsch H: Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine. 2002, 20 (Suppl 3): S34-39.
MacLeod MK, McKee AS, David A, Wang J, Mason R, Kappler JW, Marrack P: Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A. 2011, 108: 7914-7919. 10.1073/pnas.1104588108
Gupta RK: Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 1998, 32: 155-172. 10.1016/S0169-409X(98)00008-8
Mazloomi E, Jazani NH, Shahabi S: A novel adjuvant, mixture of alum and the beta-adrenergic receptor antagonist propranolol, elicits both humoral and cellular immune responses for heat-killed salmonella typhimurium vaccine. Vaccine. 2012, 30: 2640-2646. 10.1016/j.vaccine.2012.02.017
Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood. 1996, 88: 202-210.
Xiang D, Sharma VR, Freter CE, Yan J: Anti-tumor monoclonal antibodies in conjunction with beta-glucans: a novel anti-cancer immunotherapy. Curr Med Chem. 2012, 19: 4298-4305. 10.2174/092986712802884303
Driscoll M, Hansen R, Ding C, Cramer DE, Yan J: Therapeutic potential of various beta-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biol Ther. 2009, 8: 218-225. 10.4161/cbt.8.3.7337
Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer DE, Yan J: Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol. 2006, 177: 1661-1669. 10.4049/jimmunol.177.3.1661
Albeituni SH, Yan J: The effects of beta-glucans on dendritic cells and implications for cancer therapy. Anticancer Agents Med Chem. 2013, 13: 689-698. 10.2174/1871520611313050003
Volman JJ, Ramakers JD, Plat J: Dietary modulation of immune function by beta-glucans. Physiol Behav. 2008, 94: 276-284. 10.1016/j.physbeh.2007.11.045
Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J: Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood. 2011, 117: 6825-6836. 10.1182/blood-2011-02-339812
Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, Yan J: Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res. 2010, 16: 5153-5164. 10.1158/1078-0432.CCR-10-0820
Higashi T, Hashimoto K, Takagi R, Mizuno Y, Okazaki Y, Tanaka Y, Matsushita S: Curdlan induces DC-mediated Th17 polarization via Jagged1 activation in human dendritic cells. Allergol Int. 2010, 59: 161-166. 10.2332/allergolint.09-OA-0103
Tian J, Ma J, Ma K, Guo H, Baidoo SE, Zhang Y, Yan J, Lu L, Xu H, Wang S: beta-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur J Immunol. 2013, 43: 1220-1230. 10.1002/eji.201242841
Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE: Impact of LL-37 on anti-infective immunity. J Leukoc Biol. 2005, 77: 451-459.
Kindrachuk J, Jenssen H, Elliott M, Townsend R, Nijnik A, Lee SF, Gerdts V, Babiuk LA, Halperin SA, Hancock RE: A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine. 2009, 27: 4662-4671. 10.1016/j.vaccine.2009.05.094
Niyonsaba F, Madera L, Afacan N, Okumura K, Ogawa H, Hancock RE: The innate defense regulator peptides IDR-HH2, IDR-1002, and IDR-1018 modulate human neutrophil functions. J Leukoc Biol. 2013, 94: 159-170. 10.1189/jlb.1012497
Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I: Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D (2) production from mast cells. Eur J Immunol. 2001, 31: 1066-1075. 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#
Lau YE, Bowdish DM, Cosseau C, Hancock RE, Davidson DJ: Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37. Am J Respir Cell Mol Biol. 2006, 34: 399-409. 10.1165/rcmb.2005-0170OC
Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Bröcker EB, Steinman RM, Enk A, Kämpgen E, Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999, 190: 1669-1678. 10.1084/jem.190.11.1669
Fuchs EJ, Matzinger P: Is cancer dangerous to the immune system?. Semin Immunol. 1996, 8: 271-280. 10.1006/smim.1996.0035
Horig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang KW, Schlom J, Kaufman HL: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother. 2000, 49: 504-514. 10.1007/s002620000146
Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P: NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res. 2009, 15: 2130-2139. 10.1158/1078-0432.CCR-08-2632
Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC: Promotion of B cell immune responses via an alum-induced myeloid cell population. Science. 2004, 304: 1808-1810. 10.1126/science.1089926
Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA: Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008, 453: 1122-1126. 10.1038/nature06939
Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O’Hagan DT, Petrilli V, Tschopp J, O'Neill LA, Lavelle EC: Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A. 2009, 106: 870-875. 10.1073/pnas.0804897106
Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, Ward SM, Seamone ME, Vilaysane A, Mucsi AD, Fong Y, Prenner E, Ling CC, Tschopp J, Muruve DA, Amrein MW, Shi Y: Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med. 2011, 17: 479-487. 10.1038/nm.2306
Cassileth BR, Yarett IR: Cancer quackery: the persistent popularity of useless, irrational ‘alternative’ treatments. Oncology (Williston Park). 2012, 26: 754-758.
Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, Ritter G, Eiermann T, Hossfeld DK, Zander AR, Jungbluth AA, Old LJ, Bokemeyer C, Kröger N: Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. 2007, 109: 1103-1112.
Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini JC, Lejeune F, Romero P, Valmori D: Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol. 2000, 165: 7253-7261. 10.4049/jimmunol.165.12.7253
Maraskovsky E, Sjolander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjölander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A: NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res. 2004, 10: 2879-2890. 10.1158/1078-0432.CCR-03-0245
Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM, Wang Y, Lu Y, Wu Y, Liu F, Liu JY, Yang JL, Lou YY, Hu B, Niu T, Wen YJ, Xiao F, Deng HX, Li J, Kan B: Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res. 2003, 63: 600-607.
Piechocki MP, Pilon SA, Wei WZ: Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods. 2002, 259: 33-42. 10.1016/S0022-1759(01)00487-2
Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, Fridman A, Bagchi A, Winkelmann CT, Gibson R, Kandimalla ER, Agrawal S, Ciliberto G, La Monica N: Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res. 2009, 15: 1575-1584. 10.1158/1078-0432.CCR-08-2628
Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang B, Mao YQ, Liu F, Wen YJ, Lei S, Luo F, Zhou LQ, Peng F, Jiang Y, Liu JY, Zhou H, Wang QR, He QM, Xiao F, Lou YY, Xie XJ, Li Q, Wu Y, Ding ZY, Hu B, Hu M, Zhang W: Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci U S A. 2001, 98: 11545-11550. 10.1073/pnas.191112198
Chauveau C, Remy S, Royer PJ, Hill M, Tanguy-Royer S, Hubert FX, Tesson L, Brion R, Beriou G, Gregoire M, Josien R, Cuturi MC, Anegon I: Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood. 2005, 106: 1694-1702. 10.1182/blood-2005-02-0494
We thank Prof. Y.Q. Wei, P. Chen and A.P. Tong (State Key Laboratory of Biotherapy and Cancer Center, Sichuan University) for their assistance in experiments. This work was supported in part by National Natural Science Foundation of China (31070815), National Major Scientific and Technological Special Project for “Significant New Drugs Development (2013ZX09102030), and Foundation for Sichuan Distinguished Young Academic and Technology Leaders (2012JQ0014).
The authors declare that they have no competing interests.
The authors’ contributions to this work are reflected in the order, with the exception of XC and LY who supervised the research and finalized the report. ML, HS and YM carried out the majority of the in vitro studies and all of the in vivo experiments. ML drafted the manuscript. YW, HZ and LL contributed to analysis and interpretation of data. Other authors participated in the design and coordination. All authors read and approved the final manuscript.
Meng Li, Huashan Shi, Yandong Mu contributed equally to this work.
Electronic supplementary material
Additional file 1: Figure S1: The effects of different PS-HH2 formulations on human PBMCs. A-C, PS and HH2 were complexed with five ratios of PS: HH2 ranging from 4:1 (wt/wt) PS: HH2 to 1:4 (wt/wt) PS: HH2. Human PBMCs (1×106 cells/ml) were stimulated with PS, HH2, or PS-HH2 formulations for 24 h. Next, IFN-γ (A), TNF-α (B), and MCP-1 (C) in the culture supernatants was determined. *P < 0.05; **P < 0.005. D and E, Minimal cytotoxicity assay of PS-HH2 formulations. Human red blood cells (D) or PBMCs (E) were stimulated with various PS-HH2 complexes, or the components alone. Following stimulation, the supernatants were collected and measured for the release of hemoglobin or LDH. D: Total hemoglobin release from red blood cells induced by PS-HH2 complexes. E: LDH release from PBMCs following stimulation with PS-HH2 complexes. All data were representative of at least 3 independent experiments. (TIFF 809 KB)
Tumor inhibition rate to all formations and mean tumor volume of all groups for each of the in vivo experiments.
Additional file 2: Table S1. The inhibition ratio (%) was calculated by the following formula: inhibition ratio (%)= [(A-B)/A]×100, where A is the average tumor weight of the control group, and B is the tumor weight of the treated group. Table S2. The mean tumor volume of all groups for each of the in vivo experiments. (DOC 40 KB)
Additional file 3: Figure S2: Body weight and histology of major organs. A, Body weight. Body weight was measured every 3 days during the entire treatment. B, Sections of heart, liver, spleen and kidney were stained with H&E. There was no obvious histological difference between the groups (magnification, 200×). (TIFF 16 MB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Li, M., Shi, H., Mu, Y. et al. Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2. Mol Cancer 13, 179 (2014). https://doi.org/10.1186/1476-4598-13-179
- Adjuvant complex
- NY-ESO-1 protein-based vaccines